India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone sublingual film.
The director of the US Patent and Trademark Office, Kathi Vidal, has unveiled long-anticipated guidance for the procedures governing the discretionary denials that can be handed down by the US Patent Trial and Appeal Board (PTAB) when declining to review a patent’s validity.
The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug.
The European Commission has opened an antitrust investigation to assess whether Switzerland-headquartered Vifor Pharma has engaged in anticompetitive conduct.
Biotech company Glycosyn has sued Abbott Laboratories for allegedly infringing its patented method for manufacturing a key ingredient in infant formula milk, found in three of Abbott’s infant formula products under the Similac brand.
Zydus Pharmaceuticals has attempted to revive an antitrust lawsuit accusing Takeda Pharmaceuticals of attempting to delay generic competition and of abusing its dominant market position.
BMS unit Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have urged the US Supreme Court to reinstate their $1.2 billion win in a patent clash with Kite Pharma, a subsidiary of Gilead.
Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.
A bipartisan group of six US senators have asked the US Patent and Trademark Office to address ‘patent thickets’, a tactic that pharmaceutical companies allegedly use to stifle competition.
Moderna’s bid to avoid a COVID-19 patent claim has been rejected by two pharma companies that are suing the vaccine manufacturer for infringing its drug delivery technology.